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Prognostic and predictive value 
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Transurethral resection of bladder tumor (TUR‑BT) and radical cystectomy (RC) are standard 
treatment options for bladder cancer (BC). Neoadjuvant chemotherapy (NAC) prior to RC improves 
outcome of some patients but currently there are no valid biomarkers to identify patients who 
benefit from NAC. Presence of cancer stem cells (CSC) has been associated with poor outcome and 
resistance to chemotherapy in various cancers. Here we studied the expression of stem cell markers 
ALDH1, SOX2 and SSEA‑4 with immunohistochemistry in tissue microarray material consisting of 
195 BC patients treated with RC and 74 patients treated with TUR‑BT followed by NAC and RC. Post‑
operative follow‑up data of up to 22 years was used. Negative to weak cytoplasmic SOX2 staining 
was associated with lymphovascular invasion and non‑organ confined disease. It was also associated 
with shortened cancer‑specific survival, but the finding was not statistically significant. Contrary to 
previous reports, none of the other tested biomarkers were associated with cancer‑specific mortality 
or clinicopathological characteristics. Neither were they associated with response to NAC. Despite the 
promising results of previously published studies, our results suggest that CSC markers ALDH1, SOX2 
and SSEA‑4 have little if any prognostic or predictive value in BC treated with RC.
Bladder cancer (BC) is the 10th most common cancer worldwide with estimated 549,000 new cases and 200,000 
deaths  annually1. The most important risk factors for BC include tobacco use, aging, male gender, and exposure 
to certain  chemicals2.
Non-muscle invasive bladder cancer (NMIBC, stage pTa-T1 tumors) is routinely treated with transurethral 
resection of bladder tumor (TUR-BT) and various intravesical treatments. However, up to 78% of these tumors 
 recur3. For muscle-invasive bladder cancer (MIBC, stage T2 or higher) radical cystectomy (RC) with pelvic 
lymphadenectomy and cisplatin-based neoadjuvant chemotherapy (NAC) are preferred when applicable. NAC 
improves 5-year progression free and overall survival in locally invasive disease by 8%2, but to date there are 
no immunohistochemical or other biomarkers to distinguish aggressive tumors from non-aggressive tumors, 
or chemotherapy responders from non-responders. Therefore, there is an unmet need of novel tools for patient 
stratification and selection.
Cancer stem cell theory dictates that similar to normal tissues, cancer tissue has a subpopulation of cancer 
stem cells (CSCs) or tumor-initiating cells that drive the proliferation of the tumor and initiate  metastasis4–7. 
Several molecular biomarkers have been used to identify CSCs. However, many gene products are associated with 
CSC-like phenotype and none of them is universal for all cancer types. Sox2, a family member of sex determin-
ing region Y (SRY) -box genes, is a key regulator of pluripotency in stem  cells8–10 and has been linked to poor 
survival in various malignancies including  BC11–14. ALDH1, a member of aldehyde dehydrogenase subfamily, 
regulates pluripotency via retinoic acid pathway and has been implicated as a CSC  biomarker15,16. ALDH1 has 
also been associated with poor outcome and clinicopathological features in  BC17–19. Stage-specific embryonic 
antigen 4 (SSEA-4) is a ganglioside present on the cell surface of embryonic stem cells and synthesized by the 
enzyme ST3Gal  II20,21. Increased expression of SSEA-4 has been linked to poor survival in various cancers includ-
ing lung, breast, prostate and  brain22–25 and SSEA-4 is also considered a potential drug target in glioblastoma 
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 multiforme23. BC cell line HTB-9 (5637) has been reported to express SSEA-426,27 but so far, the expression of 
SSEA-4 has not been studied in clinical BC specimens in more detail.
Importantly, there is data that the number of CSCs is enriched in cisplatin-resistant subclone of T24 bladder 
cancer cell line (DR-24T) compared to parental cells and these cells were more tumorigenic in mouse xenograft 
 studies28. Prompted by aforementioned findings, we studied the expression of three CSC-related biomarkers, 
ALDH1, SOX2 and SSEA-4 in two different cohorts of BC patients treated with either RC or TUR-BT, followed 
by NAC and RC. To our surprise, none of tested markers were statistically significantly associated with disease 
progression in our patient cohorts. Neither were there significant correlations with patients’ NAC response 
implying that ALDH1, SOX2 and SSEA-4 play no major role in the progression of BC and/or multiple other 
factors determine the aggressiveness of the disease.
Results
Patient cohort. Patient characteristics of RC only cohort (n = 195) and NAC cohort (n = 74) are shown 
in Table 1. Patients included into NAC cohort underwent TUR-BT and received either 2–6 cycles of cisplatin-
gemcitabine (68 of 74 patients) or carboplatin-gemcitabine (6 of 74 patients) prior to cystectomy.
Staining patterns. Immunohistochemical ALDH1, SOX2 and SSEA-4 stainings were successful from 173, 
167, and 170 patients included into RC cohort, respectively. Representative examples of negative, weakly, and 
strongly stained carcinoma cells, as well as typical staining pattern on benign urothelium are shown in Fig. 1. 
None of the markers were associated with age, gender or smoking.
For ALDH1, there were clear differences in cytoplasmic staining intensity between individual patients’ tumors 
(from negative to strongly expressing cells) while the normal urothelium was generally negative (Fig. 1). H-score 
of ALDH1 was greater than 0 in 48 (28%) tumors and 4 or more in 22 (13%) tumors (Table 2).
SOX2 staining was found either cytoplasmic or nuclear in a proportion of tumors while the majority showed 
both the localizations (Fig. 1). This prompted us to analyze SOX2 staining patterns separately. Apparent nuclear 
SOX2 staining was detected in 119 (71%) tumors and cytoplasmic staining in 141 (84%) tumors (Table 2). In 
normal urothelium there was generally a strong cytoplasmic staining throughout the urothelium and some 
positively stained nuclei mostly concentrated at the basal or suprabasal layer of urothelium (Fig. 1).
Ganglioside SSEA-4 was generally absent in normal urothelium while many tumor cells showed positive 
staining in the cytoplasm or partially at the plasma membrane (Fig. 1). For SSEA-4, H-score was greater than 0 
in 64 (38%) tumors and 4 or more in 33 (19%) tumors (Table 2).
Association with clinicopathological characteristics and cancer‑specific survival. Based on pre-
vious published studies we first tested the prognostic value of ALDH1 in a RC cohort. H-score of 4 or more was 
not associated with carcinoma grade, stage (organ confinement) or lymphovascular invasion (LVI). Neither was 
there any significant difference in cancer-specific survival between the high and low expression groups (Table 3 
and Fig. 2a).
For cytoplasmic SOX2, a low H-score (3 or lower) was associated with LVI and non-organ confined disease 
but not with histological grade (Table 3). In support, high cytoplasmic SOX2 expression was associated with 
improved cancer-specific survival although this failed to show statistically significant difference (Fig. 2c). Nuclear 
staining of SOX2 showed no association with any clinicopathological characteristic or survival (Table 3 and 
Fig. 2b).
For SSEA-4, H-score of 4 or higher was inversely associated with high grade, but not with LVI or cancer-
specific survival (Table 3 and Fig. 2d). In addition, H-score of 4 or higher was marginally associated with organ-
confined disease (Table 3).
Co‑expression of ALDH1, SOX2 and SSEA‑4 in bladder cancer. Potential co-expression of all the 
studied markers was further tested using data from all RC samples. 95% confidence interval for relative risk 
for high H-score (4 or more) was calculated between all markers. High ALDH1 staining intensity was margin-
ally associated with nuclear SOX2. Furthermore, the nuclear SOX2 was associated with cytoplasmic SOX2 as 
expected. 95% Confidence intervals of risk ratios are shown in Table 4.
CSC markers as predictors of neoadjuvant chemotherapy. TMA samples from TUR-BT operations 
prior NAC were available from 65 patients for ALDH1 and 66 patients for SOX2 and SSEA-4 staining. Of these 
patients, 39, 36 and 40 respectively had also residual tumor in RC specimens after NAC. For any of the markers 
tested, H-score 4 or higher did not predict response to NAC (Table 5). To test the hypothesis that cancer stem 
cells are enriched in chemoresistant tumors and further after chemotherapy due to drug resistance, we compared 
the distributions of different H-scores of both chemosensitive and chemoresistant primary tumors to chemore-
sistant RC residual tumors. There was an enrichment of high H-score tumors for ALHD1 and SOX2 (N and C) 
after NAC but these differences failed to show statistically significant difference (Fig. 3).
Discussion
In the present study, we evaluated the expression and prognostic and predictive value of stem cell markers 
ALDH1, SOX2 and SSEA-4 in two different MIBC cohorts treated either with RC only, or with RC after NAC. 
Based on previously published  reports14,17–19,28 we originally hypothesized that BC patients whose carcinomas 
are enriched in CSCs would show less favorable clinicopathological characteristics, more frequent resistance 
to chemotherapy and shortened disease specific survival. Furthermore, if CSCs were in fact more resilient to 
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chemotherapy, they were expected to enrich following NAC treatment. To our surprise, we found no strong evi-
dence to support our initial hypotheses or previously published studies. The only exception was low cytoplasmic 
SOX2 staining, which was associated with LVI, non-organ confined disease and to some extent, shortened disease 
specific survival. To further confirm our findings, we repeated all the analyses using either staining intensity or 
proportion of positively stained cells alone as a read-out but found no major difference in the results (data not 
shown).
The association of ALDH1 with high clinicopathological grade, increased tumor size and poor differentiation 
has been found in multiple  studies17–19,29. The same studies found an association between high ALDH1 expres-
sion and poor disease specific survival. For SOX2, a single study found an association between high expression 
Table 1.  Baseline characteristics of patients. a Based on histopathological review of cystectomy specimen for 
RC cohort and TUR-BT for NAC cohort, respectively.
RC only cohort, n (%) NAC cohort, n (%)
Patients total 195 (100) 74 (100)
Age
Mean/median (range) 63/65 (35–80) 64/65 (47–76)
Gender
Male 160 (82) 62 (84)
Smoking
Yes 99 (51) 55 (74)
pT category in cystectomy
T0 0 (0) 29 (39)
pTa, pTis, pT1 94 (48) 16 (22)
pT2 41 (21) 13 (18)
pT3 48 (25) 11 (15)
pT4 12 (6) 5 (7)
Lymphovascular invasion in RC specimen
Yes 66 (34) 11 (15)
Grade (WHO 1973)a
G1 9 (5) 1 (1)
G2 69 (35) 18 (24)
G3 115 (59) 50 (68)
Data not available/applicable 2 (1) 5 (7)
Grade (WHO/ISUP 2004) a
Low grade 9 (5) 1 (1)
High grade 184 (94) 68 (92)
Data not available/applicable 2 (1) 5 (7)
Histological typea
Urothelial 187 (96) 69 (93)
Squamous Cell Carcinoma 5 (3) 1 (1)
Adenocarcinoma 3 (2) 0 (0)
Small cell/neuroendocrine 0 (0) 4 (7)
Adjuvant chemotherapy
Yes 1 (0) 7 (9)
Follow-up time (years)
Mean/median (range) 5.5/3.7 (0.1–22) 3.2/3.3 (0.3–8.3)
Status
Alive, no evidence of disease 50 (26) 55 (74)
Alive with recurrence 1 (0) 2 (3)
Death from bladder cancer 70 (36) 14 (19)
Death from other reason 55 (28) 3 (4)
Lost for follow-up 19 (10) 0 (0)
Pathological response to NAC
Complete response (pT0) N/A 28 (38)
Partial response (pT1/pTa/pTis) N/A 15 (20)
No response N/A 11 (15)
Progression (pT3 and/or N+) N/A 19 (26)
Data not available N/A 1 (1)
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and poor clinicopathological characteristics and survival in  NMIBC14. Even though our results regarding the 
prognostic value of studied biomarkers were different from others’, the frequencies of both ALDH1 and SOX2 
expression were congruent with previous studies. The reason for the different results of current and previous 
studies can only be speculated. However, it is important to note that SOX2 was previously evaluated in NMIBC 
cohort while ours consists of MIBC patients. Since NMIBCs more frequently harbor FGF3 mutations and MIBCs 
are enriched in TP53 and Rb  mutations30 it is possible that these differences in molecular pathogenesis override 
the effects of CSC phenotype. While the patients’ mean age and smoking history in all the cohorts were relatively 
similar, it is also possible that differences in the expression of CSC markers and outcome are influenced by other 
risk factors and/or ethnic background of the patients. Equally, the differences in staining methods and antibody 
clones used may also explain the discordant results.
In many cancer types, such as oral squamous cell carcinoma and colorectal carcinoma both nuclear and 
cytoplasmic localizations of SOX2 have been previously reported while in lung squamous cell carcinoma and 
Figure 1.  Representative examples of normal benign urothelium and negatively, weakly and strongly stained 
carcinoma tissue for ALDH1, SOX2 and SSEA-4. For SOX2, both weak/strong cytoplasmic and nuclear 
expression patterns are shown (nuclear staining pattern on the top half and cytoplasmic on the bottom).
Table 2.  Results of immunohistochemical staining from the RC-only cohort. a H-score (0–8) = staining 
intensity score (0–2) multiplied by proportion score (0–4). b Negative. c Nuclear expression pattern. 
d Cytoplasmic expression pattern.
Proportion of positive cells, n (%) Staining intensity, n (%) H-score, n (%)a
Marker 0 1–25 26–50 51–75 76–100 Neg.b Weak Strong 0 1–3 4–6 7–8
ALDH1 125 (72) 25 (14) 9 (5) 4 (2) 10 (6) 125 (72) 12 (7) 36 (21) 125 (72) 26 (15) 12 (7) 10 (6)
SOX2  (Nc) 48 (29) 60 (36) 16 (10) 15 (9) 28 (11) 48 (29) 16 (10) 103 (62) 48 (29) 60 (36) 31 (19) 28 (17)
SOX2  (Cd) 26 (16) 13 (8) 11 (7) 23 (14) 94 (56) 26 (16) 26 (16) 115 (69) 26 (16) 27 (16) 24 (14) 90 (54)
SSEA-4 105 (62) 16 (9) 8 (5) 14 (8) 27 (16) 105 (62) 37 (22) 28 (16) 105 (62) 31 (18) 18 (11) 15 (9)
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nasopharyngeal carcinoma nuclear localization appears to  predominate31,32. The nuclear import and export of 
SOX2 is regulated by phosphorylation at  Thr11833 and acetylation at  Lys7534, respectively, and the phosphoryla-
tion of SOX2 is considered crucial for stem cell self-renewal or  reprogramming33. Nevertheless, the data from 
different malignancies suggests that cytoplasmic and nuclear SOX2 may have diverse functions. Likewise, in 
our patient material both cytoplasmic and nuclear localizations were observed and associated with each other. 
Interestingly, low cytoplasmic staining was associated with LVI and non-organ confined disease, and to some 
extent, predicted less favorable survival after RC (Table 3 and Fig. 2C). Correspondingly, one would assume 
Table 3.  Staining associations with clinicopathological characteristics in the RC-only cohort. Number of 
patients is shown in brackets for each subgroup. Comparison between high (H-score ≥ 4) and low (H-score < 4) 
expression. 95% Confidence intervals for risk ratio not including 1.0 are underlined. a Lymphovascular 
invasion. b Grade 3/3 according to WHO 1973 criteria. c Organ confinement defined by pT class 2 or lower and 
absence of lymph node metastasis. 
Variable
LVIa G3 vs. other (1973)b Organ  confinedc
RR 95% CI RR 95% CI RR 95% CI
ALDH1
Low (151) Reference Reference Reference
High (22) 0.98 0.55–1.78 1.25 0.94–1.68 0.92 0.64–1.33
SOX2 (N)
Low (108) Reference Reference Reference
High (59) 0.92 0.61–1.40 1.04 0.82–1.33 1.12 0.88–1.42
SOX2 (C)
Low (53) Reference Reference Reference
High (114) 0.64 0.43–0.93 1.09 0.84–1.42 1.38 1.02–1.86
SSEA-4
Low (136) Reference Reference Reference
High (33) 1.01 0.62–1.67 0.53 0.33–0.85 1.27 1.00–1.61
Figure 2.  Kaplan–Meier survival analysis based on high (H-score ≥ 4) and low (H-score < 4) expression of 
ALDH1 (a), nuclear SOX2 (b), cytoplasmic SOX2 (c) and SSEA-4 (d) after RC in the RC-only cohort.
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Table 4.  Association of different markers in the RC-only cohort. Table shows 95% confidence interval of 
relative risk for high expression (H-score ≥ 4) of a marker on the column when expression of another marker 
on a row is high. For example, high expression of ALDH1 is associated with high nuclear expression of SOX2. 
Confidence intervals not including 1.0 are underlined.
95% CI ALDH1 SSEA-4 SOX2 (N) SOX2 (C)
ALDH1 N/A 0.22–1.58 1.16–2.41 0.88–1.40
SSEA-4 0.22–1.58 N/A 0.42–1.28 0.82–1.34
SOX2 (N) 1.17–3.81 0.35–1.33 N/A 1.37–1.96
SOX2 (C) 0.68–2.57 0.59–2.15 2.05–7.9 N/A
Table 5.  Association between high expression (H-score ≥ 4) of markers in TUR-BT samples and neoadjuvant 
chemotherapy response, where low expression (H-score < 4) is reference. Number of patients is shown in 
brackets for each subgroup. a There was no disease progression among the patients with high SSEA-4 H-score, 




other Progression vs. other
RR 95% CI RR 95% CI RR 95% CI
ALDH1
Low (48) Reference Reference Reference
High (17) 0.7 0.32–1.53 0.77 0.45–1.30 1.39 0.57–3.30
SOX2 (N)
Low (36) Reference Reference Reference
High (30) 0.67 0.37–1.22 0.94 0.64–1.38 0.6 0.23–1.56
SOX2 (S)
Low (33) Reference Reference Reference
High (33) 0.94 0.54–1.65 1.09 0.75–1.59 0.82 0.34–2.01
SSEA-4
Low (62) Reference Reference Reference
High (4) 1.24 0.44–3.46 0.82 0.30–2.22 N/Aa N/Aa
Figure 3.  Distributions of H-scores before (TUR-BT) and after (RC) neoadjuvant chemotherapy. The first 
p-value denotes the statistical difference between TUR-BT chemosensitive and RC chemoresistant tumors while 
the latter denotes the statistical difference between TUR-BT chemoresistant and RC chemoresistant tumors.
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that high nuclear SOX2 staining indicates high SOX2 transcriptional activity and poor survival but this proved 
not to be the case and the more detailed action of SOX2 in different subcellular localizations of CSCs clearly 
warrants further studies.
To our knowledge, there is no previously published data about co-expression of ALDH1, SOX2 and SSEA-4 in 
BC, nor studies on enrichment of these markers post chemotherapy. Furthermore, ours is the first to investigate 
the role of SSEA-4 in BC patient material. Although all three are implicated in pluripotency of stem cells, they 
have vastly different cellular functions and signaling  pathways8–10,15,16,20. Despite all of them being regarded as 
CSC markers and thus expected to reflect similar features in cancer cells, they were not significantly co-expressed 
in our study material. Further studies are needed to confirm this finding, but it appears clear that none of the 
CSC markers are universal and there may be multiple CSC subclones with different immunophenotypes within 
the tumors. Great individual variability in CSC number within tumors is commonly known and was predict-
ably demonstrated in our results as well. Furthermore, there is still relatively little knowledge about the inter-
actions of different CSC markers and the cellular mechanisms of their effects. CSCs are interacting with their 
surrounding non-malignant cells, and it can be speculated that some CSC biomarkers may display relevance to 
disease progression only within certain microenvironment. Taken together, a more detailed understanding of 
the underlying mechanisms of action of different CSC biomarkers could pave way for better biomarkers or sets 
of biomarkers in the  future4–6.
Despite the pessimistic overall results, the strengths of this study include analysis of multiple CSC markers 
in parallel, a long follow-up time, low drop-out rate, and the inclusion of both neoadjuvant treated and chemo-
therapy naïve patients. The main weaknesses of our study are its retrospective nature, and the small sample size of 
NAC cohort. One could also question whether TMA material is representative regarding the overall expression of 
studied CSC markers within the tumor. However, we want to emphasize that up to three cores from each tumor 
were analyzed with highly similar results suggesting that the expression of studied markers is relatively uniform.
In conclusion, our results cast doubt on the reliability of ALDH1 and SOX2 as clinically relevant prognostic 
biomarkers in bladder cancer. We also conclude that SSEA-4 was neither prognostic nor predictive biomarker 
in our material, but this needs to be confirmed in the follow-up studies.
Materials and methods
Study population. The study population consisted of 195 RC patients treated at Turku University Hospital 
between 1985 and 2005 (RC cohort) and 74 patients who underwent TUR-BT prior to NAC and RC between 
2007 and 2013 at either Turku University Hospital or Helsinki University Hospital (NAC cohort). All the patients 
included in the study had histologically confirmed MIBC (pT2 or higher) at TUR-BT and/or muscular invasion 
in imaging. The treatment was based on the European Association of Urology (EAU) guidelines at any given 
time. The clinical follow-up data was collected from hospital registries and survival data from the Finnish Can-
cer Registry. Informed consent was obtained from all subjects involved in the study.
Tissue microarrays. Diagnostic formalin-fixed and paraffin-embedded tissue blocks were collected from 
pathology archives of the Turku and Helsinki University Hospitals. The tumors were reviewed by two expert 
uro-pathologists and classified based on both the WHO 1973 and WHO/ISUP 2004 classifications. Three tissue 
cores of 1 mm in diameter were punched from representative tumor areas for each patient and transferred into 
recipient tissue microarray (TMA) blocks. In addition, one tissue core from morphologically benign urothelium 
for each patient was included into TMA whenever available in original tissue blocks. TMA was created from RC 
and TUR-BT specimens in both cohorts.
Immunohistochemistry. TMA sections were cut at four micrometer thickness, deparaffinized with xylene 
and rehydrated in graded series of alcohol. The sections were pretreated with Target Retrieval Solution (Dako) 
pH 6 (for SSEA-4) or pH 9 (for ALDH1 and SOX2), microwaved twice for 7 min and then washed three times 
with Tris–HCl buffer solution. Slides were next incubated in 3% hydrogen peroxide solution for 10 min, washed 
three times with Tris–HCl buffer solution and incubated for 10 min in Normal antibody diluent (Immunologic 
BD09-125). Mouse monoclonal IgG3 anti-human SSEA-4 antibody (clone MC-813-70, 1:1000, STEMCELL 
Technologies, Vancouver, Canada), mouse monoclonal IgG1 antibody against human ALDH1 aa. 7–128 (clone 
44/ALDH, 1:200, BD Transduction Laboratories, NJ, USA) and mouse monoclonal IgG1 anti-human SOX2 
(clone E-4, 1:500, Santa Cruz Biotechnology, Dallas, USA) were diluted in Normal antibody diluent and applied 
on the sections for 1 h. After washing three times with Tris–HCl buffer solution, the primary antibodies were 
detected with Brightvision + goat anti-mouse/rabbit HRP secondary antibodies (DPVB110HRP, Immunologic) 
for SSEA-4 and ALDH1A1, and EnVision + Dual Link HRP (Dako) for SOX2 for 20–30 min, followed by DAB 
substrate (Dako K3468) for 10 min. After washing three times with distilled water, the sections were counter-
stained with Mayer’s Hematoxylin Solution. BenchMark XT automated IHC/ISH slide staining system (Ventana 
Medical Systems, Inc.) was used for all the stainings and multiple staining conditions were tested for each anti-
body to achieve optimal staining results before staining the TMA material. Liver and testis were used as positive 
controls for ALDH1, benign urothelium for SOX2, and testis for SSEA-4. Lymphoid tissue was used as a negative 
control for all the antibodies.
All the slides were digitized using Pannoramic 250 scanner (3DHistech Ltd, Budapest, Hungary), viewed with 
CaseCenter software (3DHistech), and scored visually on a computer screen as follows: negative = 0, weak = 1, 
strong = 2. The most strongly stained carcinoma cells were first selected as a reference for high expression for each 
biomarker used. Carcinoma cells with no staining or equal to non-specific background were considered negative. 
Up to three carcinoma samples from each patient were analyzed and the cases with unsatisfactory tumor samples 
(e.g. tissue lost on the slide or no carcinoma cells in the TMA sample) were excluded from the final data analysis. 
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The proportion of positively stained carcinoma cells was graded by approximation as follows: 0 for < 1% posi-
tive cells, 1 for 1–25% positive cells, 2 for 26–50% positive cells, 3 for 51–75% positive cells and 4 for 76–100% 
positive cells. Histological staining score (H-score) was calculated by multiplying the staining intensity score 
by the proportion score resulting in a number 0–8. In the final analysis, H-score of 4 or higher was considered 
high expression for each biomarker studied. Since morphologically benign tissue was not available from all the 
patients and these tissues may carry precancerous genomic alterations, the marker status in morphologically 
benign urothelium was not analyzed quantitatively.
Statistical analyses. The Kaplan–Meier method was used in survival analysis in Fig.  2. Pearson’s chi-
squared test was used in Fig. 3 and Tables 3, 4 and 5. In the NAC cohort (Fig. 3), the cases lacking carcinoma 
tissue in cystectomy specimen were considered chemosensitive whereas the cases with viable residual/recidive 
carcinoma in cystectomy specimen were considered chemoresistant.
Institutional review board statement. The study was conducted according to the guidelines of the Dec-
laration of Helsinki, and approved by the Research Ethics Board of the Hospital District of Southwest Finland 
(1.8.2006/301).
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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